Quantcast

Latest Actavis Stories

2014-06-10 16:28:17

DUBLIN, June 10, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to...

2014-06-10 08:31:35

DUBLIN, June 10, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes. Actavis intends to use the net proceeds from the offering, along with borrowings under its indirect subsidiary Actavis Capital S.a r.l.'s new senior unsecured term loan facilities, other financings and cash on hand, (a) to consummate the acquisition of Forest Laboratories, Inc....

2014-06-09 20:22:33

- Terms Unchanged from Previously Disclosed Agreement - DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol(®) HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013. Under the terms of the...

2014-06-09 08:28:52

DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) (the "Company") today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes") of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations"). The Consent Solicitations were originally scheduled to...

2014-05-30 16:25:02

DUBLIN, May 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil(® )(armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil(®) is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or...

2014-05-27 16:25:33

DUBLIN, May 27, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes....

2014-05-23 08:24:32

CHAGRIN FALLS, Ohio, May 23, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces the appointment of Gary Rojewski as its new CEO, effective June 2, 2014. Mr. Rojewski will be responsible for leading and managing EnzymeBioSystems' business operations, including regulatory affairs with government agencies. Mr. Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter and Gamble Pharmaceuticals (PG), Warner...

2014-05-22 08:30:15

DUBLIN, May 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition") of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Forest is soliciting consents ("Consents") from holders of its securities listed in the...

2014-05-21 08:29:22

DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after menopause. Up to...

2014-05-15 08:33:22

DUBLIN, May 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta(®) (methylphenidate hydrochloride extended-release tablets). Under the terms of the extended exclusive supply and distribution agreement -- which was first agreed to by the companies in November 2010 and due to expire on December 31, 2014 -- JPI will continue to...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related